A Radioactive Drug Aimed at Tumors Was Tested in Mice
Original title: Macropa-Based 225Ac-Labeled RGD Peptides for Targeted Alpha Therapy.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done in animals, not people. Most findings at this stage never become treatments.
This was only done in cells in the lab and in mice.
The short version
Scientists built a new drug that carries radiation straight to tumor cells, and it slowed tumor growth in mice.
What was studied. Researchers made two new drugs that use a carrier called Macropa to hold a radioactive metal, actinium 225, and deliver it to tumors. They tested both in tumor cells in the lab and in mice, including mice with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary brain tumors. They also tested adding a second compound called homoarginine.
What they found. The version with two targeting arms got into tumor cells better than the single arm version, and it killed more of those cells. In mice with colon tumors, it built up in the tumor more and slowed tumor growth. In glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary cells in the lab, adding homoarginine made it kill more cells. But in mice with glioblastoma in the brain, adding homoarginine did not help.
What this means, and what it doesn't
What it could mean: This is an early idea for a new way to aim radiation at tumor cells. It showed some promise in animals. Nothing about it changes the care you can get right now.
What it doesn't mean: This does not mean a new treatment is close. The work was done in cells in a dish and in mice, not in people. It has not been tested for safety in humans. It is not a cure. The researchers themselves say the drug needs more work before it can move forward.
Source: PubMed, August 3, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.